𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The combined use of stents and abciximab confers a `pronounced benefit' for patients with complex coronary atherosclerotic lesions undergoing percutaneous coronary interventions

Book ID
120869230
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2000
Weight
133 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Abciximab and angiographic restenosis af
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—A double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel
✍ Helmut Schühlen; Adnan Kastrati; Julinda Mehilli; Jörg Hausleiter; Josef Dirschi 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 163 KB
Rationale and design of the dual antipla
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions
✍ Laura Mauri; Dean J. Kereiakes; Sharon-Lise T. Normand; Stephen D. Wiviott; Davi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 307 KB